Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Golubnitschaja O, Debald M, Yeghiazaryan K et al. Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. Doi:10.1007/s13277-016-5168-x (2016) (In press). •• Demonstrating an urgent necessity for paradigm shift in the overall breast cancer management from reactive to predictive, preventive and personalized medical services, summarizing all-known breast cancer-related risk factors and providing recommendations for innovative multilevel diagnostic approaches.
  MedlineGoogle Scholar
• 2 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 3 Ekwueme DU, Guy GP, Rim SH et al. Health and economic impact of breast cancer mortality in young women, 1970–2008. Am. J. Prev. Med. 46(1), 71–79 (2014).
  MedlineGoogle Scholar
• 4 Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378(9805), 1812–1823 (2011).
  Medline CASGoogle Scholar
• 5 Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108(11), 2205–2240 (2013).
  Medline CASGoogle Scholar
• 6 Golubnitschaja O, Yeghiazaryan K, Costigliola V et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 4(1), 6 (2013). •• Summarizing protein biomarker panels specific for breast cancer development and progression and providing complete information about functional groups involved in BC pathology; the paper useful for creation of individualized patient profiles, targeted prediction and prevention of breast cancer.
  MedlineGoogle Scholar
• 7 Luengo-fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14(12), 1165–1174 (2013).
  MedlineGoogle Scholar
• 8 Meneses K, Azuero A, Hassey L, Mcnees P, Pisu M. Does economic burden influence quality of life in breast cancer survivors? Gynecol. Oncol. 124(3), 437–443 (2012).
  MedlineGoogle Scholar
• 9 Wang L, Xiao Y, Ping Y et al. Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer. PLoS ONE 9(8), e104282 (2014). • Demonstrating high level of clinical utility for multidimensional (multiomics) data to identify the cancer-related pathways and to improve the precision of diagnosis.
  MedlineGoogle Scholar
• 10 Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin. Genet. 85(1), 43–48 (2014).
  Medline CASGoogle Scholar
• 11 Garrisi VM, Tommasi S, Facchiano A et al. Proteomic profile in familial breast cancer patients. Clin. Biochem. 46(3), 259–265 (2013).
  Medline CASGoogle Scholar
• 12 Rhee JK, Kim K, Chae H et al. Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res. 41(18), 8464–8474 (2013).
  Medline CASGoogle Scholar
• 13 Xu H, Eirew P, Mullaly SC, Aparicio S. The omics of triple-negative breast cancers. Clin. Chem. 60(1), 122–133 (2014).
  Medline CASGoogle Scholar
• 14 Muellner MK, Mair B, Ibrahim Y et al. Targeting a cell state common to triple-negative breast cancers. Mol. Syst. Biol. 11(1), 789 (2015).
  MedlineGoogle Scholar
• 15 Chen S. An “omics” approach to determine the mechanisms of acquired aromatase inhibitor resistance. OMICS 15(6), 347–352 (2011).
  Medline CASGoogle Scholar
• 16 Kim D, Li R, Dudek SM, Ritchie MD. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer. J. Biomed. Inform. 56, 220–228 (2015).
  MedlineGoogle Scholar
• 17 Pauling JK, Christensen AG, Batra R et al. Elucidation of epithelial–mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysis. Integr. Biol. (Camb.) 6(11), 1058–1068 (2014).
  Medline CASGoogle Scholar
• 18 Ternès N, Arnedos M, Koscielny S, Michiels S, Lanoy E. Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. Curr. Opin. Oncol. 26(6), 576–583 (2014).
  Medline CASGoogle Scholar
• 19 Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-generation sequencing in breast cancer: first take home messages. Curr. Opin. Oncol. 24(6), 597–604 (2012). • Summarizing the role of next-generation sequencing in breast cancer diagnostics, providing information for novel targets for treatments and disease monitoring tailored to the person.
  Medline CASGoogle Scholar
• 20 Ahsan H, Halpern J, Kibriya MG et al. A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol. Biomarkers Prev. 23(4), 658–669 (2014).
  Medline CASGoogle Scholar
• 21 Lindström S, Thompson DJ, Paterson AD et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat. Commun. 5, 5303 (2014).
  Medline CASGoogle Scholar
• 22 Michailidou K, Beesley J, Lindstrom S et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat. Genet. 47(4), 373–380 (2015).
  Medline CASGoogle Scholar
• 23 Hsiung CN, Chu HW, Huang YL et al. Functional variants at the 21q22.3 locus involved in breast cancer progression identified by screening of genome-wide estrogen response elements. Breast Cancer Res. 16(5), 455 (2014).
  MedlineGoogle Scholar
• 24 Purrington KS, Slager S, Eccles D et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35(5), 1012–1019 (2014).
  Medline CASGoogle Scholar
• 25 Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J. Surg. Oncol. 111(1), 66–80 (2015).
  MedlineGoogle Scholar
• 26 Abu-khalf M, Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. Breast 22(Suppl. 2), S83–S87 (2013).
  MedlineGoogle Scholar
• 27 Fostira F, Tsitlaidou M, Papadimitriou C et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res. Treat. 134(1), 353–362 (2012).
  Medline CASGoogle Scholar
• 28 Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin. Cancer Res. 21(1), 211–220 (2015).
  Medline CASGoogle Scholar
• 29 Silwal-pandit L, Vollan HK, Chin SF et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin. Cancer Res. 20(13), 3569–3580 (2014).
  Medline CASGoogle Scholar
• 30 He JM, Pu YD, Wu YJ et al. Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. Genet. Mol. Res. 13(4), 8925–8931 (2014).
  Medline CASGoogle Scholar
• 31 Liang H, Yan Y, Li T et al. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies. Tumour Biol. 35(2), 1695–1701 (2014).
  Medline CASGoogle Scholar
• 32 Wang ZG, Cui W, Yang LF, Zhu YQ, Wei WH. Association of dietary intake of folate and MTHFR genotype with breast cancer risk. Genet. Mol. Res. 13(3), 5446–5451 (2014).
  Medline CASGoogle Scholar
• 33 Li K, Li W, Dong X. Association of 677 C>T (rs1801133) and 1298 A>C (rs1801131) polymorphisms in the MTHFR gene and breast cancer susceptibility: a meta-analysis based on 57 individual studies. PLoS ONE 9(6), e71290 (2014).
  MedlineGoogle Scholar
• 34 Diakite B, Tazzite A, Hamzi K, Jouhadi H, Nadifi S. Methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Moroccan women. Afr. Health Sci. 12(2), 204–209 (2012).
  Medline CASGoogle Scholar
• 35 Awwad N, Yousef AM, Abuhaliema A, Abdalla I, Yousef M. Relationship between genetic polymorphisms in MTHFR (C677T, A1298C and their Haplotypes) and the incidence of breast cancer among Jordanian females – case–control study. Asian Pac. J. Cancer Prev. 16(12), 5007–5011 (2015).
  MedlineGoogle Scholar
• 36 Qi X, Ma X, Yang X et al. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res. Treat. 123(2), 499–506 (2010).
  Medline CASGoogle Scholar
• 37 Xie H, Xia K, Rong H, Chen X. Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women. Breast 22(5), 707–712 (2013).
  MedlineGoogle Scholar
• 38 Zhang N, Huo Q, Wang X et al. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis. Gene 535(2), 170–176 (2014).
  Medline CASGoogle Scholar
• 39 Krześlak A, Forma E, Jóźwiak P et al. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin. Exp. Med. 14(1), 107–113 (2014).
  Medline CASGoogle Scholar
• 40 Karakas B, Colak D, Kaya N et al. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biol. Ther. 14(10), 888–896 (2013).
  Medline CASGoogle Scholar
• 41 Park HS, Jang MH, Kim EJ et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27(9), 1212–1222 (2014).
  Medline CASGoogle Scholar
• 42 Park YH, Jung HH, Do IG et al. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. Int. J. Cancer 136(8), 1976–1984 (2015).
  Medline CASGoogle Scholar
• 43 Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl Cancer Inst. 98(10), 671–680 (2006).
  Medline CASGoogle Scholar
• 44 Bostner J, Ahnström waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26(49), 6997–7005 (2007).
  Medline CASGoogle Scholar
• 45 Lu X, Mazur SJ, Lin T, Appella E, Xu Y. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 33(20), 2655–2664 (2014).
  Medline CASGoogle Scholar
• 46 Wang D, Lu P, Zhang H et al. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget 5(21), 10803–10815 (2014).
  MedlineGoogle Scholar
• 47 Yin ZQ, Liu JJ, Xu YC et al. A 41-gene signature derived from breast cancer stem cells as a predictor of survival. J. Exp. Clin. Cancer Res. 33(1), 49 (2014).
  Medline CASGoogle Scholar
• 48 Meldi KM, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Transl. Res. 165(1), 102–114 (2015).
  Medline CASGoogle Scholar
• 49 Jovanovic J, Rønneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol. Oncol. 4(3), 242–254 (2010).
  Medline CASGoogle Scholar
• 50 Locke WJ, Zotenko E, Stirzaker C et al. Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. Clin. Epigenetics 7(1), 52 (2015). •• Summarizing epigenetic networks and demonstrating biological value and potential clinical utility of epigenome-wide maps for early breast carcinogenesis.
  MedlineGoogle Scholar
• 51 Győrffy B, Bottai G, Fleischer T et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int. J. Cancer 138(1), 87–97 (2016).
  Medline CASGoogle Scholar
• 52 Li Y, Melnikov AA, Levenson V et al. A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer 15, 417 (2015).
  Medline CASGoogle Scholar
• 53 Li Z, Guo X, Wu Y et al. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Res. Treat. 149(3), 767–779 (2015).
  Medline CASGoogle Scholar
• 54 Müller BM, Jana L, Kasajima A et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer – overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13(1), 215 (2013).
  Medline CASGoogle Scholar
• 55 Seo J, Min SK, Park HR et al. Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J. Breast Cancer 17(4), 323–331 (2014).
  MedlineGoogle Scholar
• 56 Park SY, Jun JA, Jeong KJ et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol. Rep. 25(6), 1677–1681 (2011).
  Medline CASGoogle Scholar
• 57 Yokoyama Y, Matsumoto A, Hieda M et al. Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res. 16(3), R66 (2014).
  MedlineGoogle Scholar
• 58 Healey MA, Hu R, Beck AH et al. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study. Breast Cancer Res. Treat. 147(3), 639–651 (2014).
  Medline CASGoogle Scholar
• 59 Zhang L, Deng L, Chen F et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 5(21), 10665–10677 (2014).
  MedlineGoogle Scholar
• 60 Feng Q, Zhang Z, Shea MJ et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 24(7), 809–819 (2014).
  Medline CASGoogle Scholar
• 61 Timms KM, Abkevich V, Hughes E et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16(6), 475 (2014).
  MedlineGoogle Scholar
• 62 Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Res. Treat. 148(3), 615–622 (2014).
  Medline CASGoogle Scholar
• 63 Xu Y, Diao L, Chen Y et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann. Oncol. 24(6), 1498–1505 (2013).
  Medline CASGoogle Scholar
• 64 Yamashita N, Tokunaga E, Kitao H et al. Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer. Clin. Breast Cancer 15(6), 498–504 (2015).
  Medline CASGoogle Scholar
• 65 Ramos EA, Grochoski M, Braun-Prado K et al. Epigenetic changes of CXCR4and its ligand CXCL12as prognostic factors for sporadic breast cancer. PLoS ONE 6(12), e29461 (2011).
  Medline CASGoogle Scholar
• 66 Wendt MK, Cooper AN, Dwinell MB. Epigenetic silencing of CXCL12increases the metastatic potential of mammary carcinoma cells. Oncogene 27(10), 1461–1471 (2008).
  Medline CASGoogle Scholar
• 67 Fridrichova I, Smolkova B, Kajabova V et al. CXCL12 and ADAM23 hypermethylation are associated with advanced breast cancers. Transl. Res. 165(6), 717–730 (2015).
  Medline CASGoogle Scholar
• 68 Verbisck NV, Costa ET, Costa FF et al. ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res. 69(13), 5546–5552 (2009).
  Medline CASGoogle Scholar
• 69 Costa FF, Verbisck NV, Salim AC et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 23(7), 1481–8 (2004).
  Medline CASGoogle Scholar
• 70 Ramos EA, Camargo AA, Braun K et al. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer 10(1), 23 (2010).
  MedlineGoogle Scholar
• 71 Kloten V, Becker B, Winner K et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15(1), R4 (2013).
  Medline CASGoogle Scholar
• 72 Kuchiba A, Iwasaki M, Ono H et al. Global methylation levels in peripheral blood leukocyte DNA by LUMA and breast cancer: a case–control study in Japanese women. Br. J. Cancer 110(11), 2765–2771 (2014).
  Medline CASGoogle Scholar
• 73 Hon GC, Hawkins RD, Caballero OL et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22(2), 246–258 (2012).
  Medline CASGoogle Scholar
• 74 Choi JY, James SR, Link PA et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 30(11), 1889–1897 (2009).
  Medline CASGoogle Scholar
• 75 Legendre C, Gooden GC, Johnson K, Martinez RA, Liang WS, Salhia B. Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. Clin. Epigenetics 7(1), 100 (2015).
  MedlineGoogle Scholar
• 76 Bernardino J, Roux C, Almeida A et al. DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet. 97(2), 83–89 (1997).
  Medline CASGoogle Scholar
• 77 Krishnan P, Ghosh S, Wang B et al. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics 16(1), 735 (2015).
  MedlineGoogle Scholar
• 78 Mcguire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 34(1), 145–155 (2015).
  Medline CASGoogle Scholar
• 79 Takahashi RU, Miyazaki H, Ochiya T. The roles of microRNAs in breast cancer. Cancers (Basel). 7(2), 598–616 (2015). •• Summarizing the role of miRNA panel in breast cancer diagnosis and treatment considering the mechanisms of tumor initiation, promotion of breast cancer metastatic disease and drug resistance as well as targeting new therapies.
  Medline CASGoogle Scholar
• 80 Chen J, Yao D, Li Y et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 32(3), 557–567 (2013).
  Medline CASGoogle Scholar
• 81 Zhang HL, Qin XJ, Cao DL et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J. Androl. 15(2), 231–235 (2013).
  Medline CASGoogle Scholar
• 82 Kim SY, Jeon TY, Choi CI et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J. Mol. Diagn. 15(5), 661–669 (2013).
  MedlineGoogle Scholar
• 83 Toiyama Y, Hur K, Tanaka K et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 259(4), 735–743 (2014).
  MedlineGoogle Scholar
• 84 Ma L, Teruya-feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682–688 (2007).
  Medline CASGoogle Scholar
• 85 Cizeron-clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C. MiR-190b, the highest up-regulated miRNA in ERα-positive compared with ERα-negative breast tumors, a new biomarker in breast cancers? BMC Cancer 15, 499 (2015).
  MedlineGoogle Scholar
• 86 Niu J, Xue A, Chi Y et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35(10), 1302–1313 (2016).
  Medline CASGoogle Scholar
• 87 Kodahl AR, Lyng MB, Binder H et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol. Oncol. 8(5), 874–883 (2014).
  Medline CASGoogle Scholar
• 88 Lin X, Chen L, Yao Y et al. CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget 6(24), 20485–20499 (2015).
  MedlineGoogle Scholar
• 89 Krishnan P, Ghosh S, Wang B et al. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics 16(1), 735 (2015).
  MedlineGoogle Scholar
• 90 Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 597145 (2011).
  MedlineGoogle Scholar
• 91 Erbes T, Hirschfeld M, Rücker G et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer 15, 193 (2015).
  MedlineGoogle Scholar
• 92 Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett. 369(1), 67–75 (2015).
  Medline CASGoogle Scholar
• 93 Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation. EPMA J. 7, 1 (2015).
  MedlineGoogle Scholar
• 94 Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: quo vadis? World J. Clin. Oncol. 5(2), 71–81 (2014).
  MedlineGoogle Scholar
• 95 Fkih M’hamed I, Privat M, Ponelle F, Penault-llorca F, Kenani A, Bignon YJ. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. Cell. Oncol. (Dordr.). 38(6), 433–442 (2015).
  MedlineGoogle Scholar
• 96 Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J. Clin. Invest. 123(1), 150–163 (2013).
  Medline CASGoogle Scholar
• 97 Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int. J. Mol. Med. 30(3), 680–686 (2012).
  Medline CASGoogle Scholar
• 98 Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283(44), 29897–29903 (2008).
  Medline CASGoogle Scholar
• 99 Wei Y, Lai X, Yu S et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 147(2), 423–431 (2014).
  Medline CASGoogle Scholar
• 100 Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem. Biophys. Res. Commun. 411(4), 804–808 (2011).
  Medline CASGoogle Scholar
• 101 Bockhorn J, Yee K, Chang YF et al. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res. Treat. 137(2), 373–382 (2013).
  Medline CASGoogle Scholar
• 102 Dobson JR, Taipaleenmäki H, Hu YJ et al. hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int. 14(1), 73 (2014).
  MedlineGoogle Scholar
• 103 Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: clinical roles and current perspectives. Exp. Mol. Pathol. 96(1), 98–107 (2014).
  Medline CASGoogle Scholar
• 104 Wang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int. J. Clin. Exp. Pathol. 8(6), 6547–6553 (2015).
  Medline CASGoogle Scholar
• 105 Zhang Y, Yang P, Sun T et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell. Biol. 15(3), 284–294 (2013).
  Medline CASGoogle Scholar
• 106 Shinden Y, Iguchi T, Akiyoshi S et al. miR-29b is an indicator of prognosis in breast cancer patients. Mol. Clin. Oncol. 3(4), 919–923 (2015).
  Medline CASGoogle Scholar
• 107 Song B, Wang C, Liu J et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J. Exp. Clin. Cancer Res. 29(1), 29 (2010).
  Medline CASGoogle Scholar
• 108 Wang Y, Zhang Y, Pan C, Ma F, Zhang S. Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis. PLoS ONE 10(2), e0118647 (2010).
  Google Scholar
• 109 Pan F, Mao H, Deng L, Li G, Geng P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int. J. Clin. Exp. Pathol. 7(9), 5622–5633 (2014).
  MedlineGoogle Scholar
• 110 Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 26(19), 2799–2803 (2007).
  Medline CASGoogle Scholar
• 111 Si H, Sun X, Chen Y et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 139(2), 223–229 (2013).
  Medline CASGoogle Scholar
• 112 Qian B, Katsaros D, Lu L et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat. 117(1), 131–140 (2009).
  Medline CASGoogle Scholar
• 113 Zeng H, Fang C, Nam S, Cai Q, Long X. The clinicopathological significance of microRNA-155 in breast cancer: a meta-analysis. Biomed. Res. Int. 2014, 724209 (2014).
  MedlineGoogle Scholar
• 114 Kong W, He L, Richards EJ et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33(6), 679–689 (2014).
  Medline CASGoogle Scholar
• 115 Zheng SR, Guo GL, Zhang W et al. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol. Rep. 27(4), 1149–1155 (2012).
  Medline CASGoogle Scholar
• 116 Erbes T, Hirschfeld M, Rücker G et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer 15, 193 (2015).
  MedlineGoogle Scholar
• 117 Shaker O, Maher M, Nassar Y, Morcos G, Gad Z. Role of microRNAs -29b-2, -155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. Gene 560(1), 77–82 (2015).
  Medline CASGoogle Scholar
• 118 Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J. Biomed. Sci. 20(1), 79 (2013).
  Medline CASGoogle Scholar
• 119 Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomarkers Prev. 21(8), 1236–1243 (2012).
  Medline CASGoogle Scholar
• 120 Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin. J. Cancer Res. 25(1), 46–54 (2013).
  MedlineGoogle Scholar
• 121 Jung EJ, Santarpia L, Kim J et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10), 2603–2614 (2012).
  Medline CASGoogle Scholar
• 122 Rothé F, Ignatiadis M, Chaboteaux C et al. Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6(6), e20980 (2011).
  Medline CASGoogle Scholar
• 123 Toyama T, Kondo N, Endo Y et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J. Clin. Oncol. 42(4), 256–263 (2012).
  MedlineGoogle Scholar
• 124 Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene 507(2), 135–138 (2012).
  Medline CASGoogle Scholar
• 125 Pérez-Rivas LG, Jerez JM, Carmona R et al. A microRNA signature associated with early recurrence in breast cancer. PLoS ONE 9(3), e91884 (2014).
  MedlineGoogle Scholar
• 126 Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O. ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J. 4(1), 22 (2013). •• Demonstrating clinical utility of multilevel diagnostics and providing recommendations for implementation of biomarker panels by innovative minimal-invasive blood analysis.
  MedlineGoogle Scholar
• 127 Coumans JV, Gau D, Poljak A, Wasinger V, Roy P, Moens PD. Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses. OMICS 18(12), 778–791 (2014).
  Medline CASGoogle Scholar
• 128 Ding Z, Joy M, Bhargava R et al. Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene 33(16), 2065–2074 (2014).
  Medline CASGoogle Scholar
• 129 Zou L, Ding Z, Roy P. Profilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation. J. Cell. Physiol. 223(3), 623–629 (2010).
  Medline CASGoogle Scholar
• 130 Bae YH, Ding Z, Zou L, Wells A, Gertler F, Roy P. Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J. Cell. Physiol. 219(2), 354–364 (2009).
  Medline CASGoogle Scholar
• 131 Sakwe AM, Koumangoye R, Guillory B, Ochieng J. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Exp. Cell. Res. 317(6), 823–837 (2011).
  Medline CASGoogle Scholar
• 132 Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-vuorinen A, Soini Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res. Treat. 138(1), 81–90 (2013).
  Medline CASGoogle Scholar
• 133 Wu QW, Yang QM, Huang YF et al. Expression and clinical significance of matrix metalloproteinase-9 in lymphatic invasiveness and metastasis of breast cancer. PLoS ONE 9(5), e97804 (2014).
  MedlineGoogle Scholar
• 134 Heo DS, Choi H, Yeom MY, Song BJ, Oh SJ. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients. Oncol. Rep. 31(4), 1567–1572 (2014).
  Medline CASGoogle Scholar
• 135 Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer 14(1), 609 (2014).
  MedlineGoogle Scholar
• 136 Liu NQ, Stingl C, Look MP et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J. Natl Cancer Inst. 106(2), djt376 (2014).
  MedlineGoogle Scholar
• 137 Schirosi L, De Summa S, Tommasi S et al. Immunoprofile from tissue microarrays to stratify familial breast cancer patients. Oncotarget 6(29), 27865–27879 (2015).
  MedlineGoogle Scholar
• 138 Tenori L, Oakman C, Morris PG et al. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol. Oncol. 9(1), 128–139 (2015).
  Medline CASGoogle Scholar
• 139 Kim SK, Jung WH, Koo JS. Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS ONE 9(6), e101004 (2014).
  MedlineGoogle Scholar
• 140 Antonov A, Agostini M, Morello M, Minieri M, Melino G, Amelio I. Bioinformatics analysis of the serine and glycine pathway in cancer cells. Oncotarget 5(22), 11004–11013 (2014).
  MedlineGoogle Scholar
• 141 Cao MD, Lamichhane S, Lundgren S et al. Metabolic characterization of triple negative breast cancer. BMC Cancer 14(1), 941 (2014).
  MedlineGoogle Scholar
• 142 Cui Y, Shu XO, Gao YT et al. Urinary prostaglandin E2 metabolite and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 23(12), 2866–2873 (2014).
  Medline CASGoogle Scholar
• 143 Fawzy MS, Aly NM, Shalaby SM, El-Sawy WH, Abdul-Maksoud RS. Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: a case–control study. Gene 527(2), 601–605 (2013).
  Medline CASGoogle Scholar
• 144 Budhu A, Terunuma A, Zhang G, Hussain SP, Ambs S, Wang XW. Metabolic profiles are principally different between cancers of the liver, pancreas and breast. Int. J. Biol. Sci. 10(9), 966–972 (2014).
  MedlineGoogle Scholar
• 145 Budczies J, Pfitzner BM, Györffy B et al. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int. J. Cancer 136(7), 1619–1628 (2015).
  Medline CASGoogle Scholar
• 146 Budczies J, Brockmöller SF, Müller BM et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J. Proteomics 94, 279–288 (2013).
  Medline CASGoogle Scholar
• 147 Van geldermalsen M, Wang Q, Nagarajah R et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene doi:10.1038/onc.2015.381 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 148 McGuirk S, Gravel SP, Deblois G et al. PGC-1α supports glutamine metabolism in breast cancer. Cancer Metab. 1(1), 22 (2013).
  MedlineGoogle Scholar
• 149 Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol. Cell. Proteomics 11(8), 422–434 (2012).
  MedlineGoogle Scholar
• 150 Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 30(3–4), 449–463 (2011).
  Medline CASGoogle Scholar
• 151 Yin K. Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade. Onco Targets Ther. 8, 1069–1074 (2015).
  Medline CASGoogle Scholar
• 152 Pesta M, Kulda V, Narsanska A, Fichtl J, Topolcan O. May CTC technologies promote better cancer management? EPMA J. 6(1), 1 (2015).
  MedlineGoogle Scholar
• 153 Wallwiener M, Hartkopf AD, Baccelli I et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res. Treat. 137(2), 503–510 (2013).
  MedlineGoogle Scholar
• 154 Pearl ML, Dong H, Tulley S et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). Gynecol. Oncol. 137(2), 229–238 (2015).
  MedlineGoogle Scholar
• 155 Torphy RJ, Tignanelli CJ, Kamande JW et al. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS ONE 9(2), e89474 (2014).
  MedlineGoogle Scholar
• 156 Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res. 31(3), 979–984 (2011).
  MedlineGoogle Scholar
• 157 Tinhofer I, Konschak R, Stromberger C et al. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 25(10), 2042–2047 (2014).
  Medline CASGoogle Scholar
• 158 Beije N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the CellSearch system: the clinician’s guide to breast cancer treatment? Cancer Treat. Rev. 41(2), 144–150 (2015).
  MedlineGoogle Scholar
• 159 Wang HY, Ahn S, Kim S et al. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Exp. Mol. Pathol. 97(3), 445–452 (2014).
  Medline CASGoogle Scholar
• 160 Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol. Diagn. Ther. 18(4), 389–402 (2014).
  MedlineGoogle Scholar
• 161 Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80(6), 1328–1332 (2012).
  MedlineGoogle Scholar
• 162 Tognela A, Spring KJ, Becker T et al. Predictive and prognostic value of circulating tumor cell detection in lung cancer: a clinician’s perspective. Crit. Rev. Oncol. Hematol. 93(2), 90–102 (2015).
  MedlineGoogle Scholar
• 163 Fu L, Liu F, Fu H et al. Circulating tumor cells correlate with recurrence in stage III small-cell lung cancer after systemic chemoradiotherapy and prophylactic cranial irradiation. Jpn J. Clin. Oncol. 44(10), 948–955 (2014).
  MedlineGoogle Scholar
• 164 Tsujiura M, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E. Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. World J. Gastroenterol. 20(12), 3265–3286 (2014).
  Medline CASGoogle Scholar
• 165 Toyoshima K, Hayashi A, Kashiwagi M et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int. J. Cancer 137(4), 991–998 (2015).
  Medline CASGoogle Scholar
• 166 Uenosono Y, Arigami T, Kozono T et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer 119(22), 3984–3991 (2013).
  MedlineGoogle Scholar
• 167 Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897–6904 (2004).
  MedlineGoogle Scholar
• 168 Wallwiener M, Riethdorf S, Hartkopf AD et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 14(1), 512 (2014).
  MedlineGoogle Scholar
• 169 Yokobori T, Iinuma H, Shimamura T et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73(7), 2059–2069 (2013).
  Medline CASGoogle Scholar
• 170 Ueo H, Sugimachi K, Gorges TM et al. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br. J. Cancer 112(9), 1519–1526 (2015).
  Medline CASGoogle Scholar
• 171 Maltoni R, Fici P, Amadori D et al. Circulating tumor cells in early breast cancer: a connection with vascular invasion. Cancer Lett. 367(1), 43–48 (2015).
  Medline CASGoogle Scholar
• 172 Nadal R, Ortega FG, Salido M et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int. J. Cancer 133(10), 2398–2407 (2013).
  Medline CASGoogle Scholar
• 173 Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339–9344 (2006).
  Medline CASGoogle Scholar
• 174 Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med. 11(1), 169 (2013).
  MedlineGoogle Scholar
• 175 Al-hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14(1), 43–47 (2004).
  Medline CASGoogle Scholar
• 176 Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res. 12(19), 5606–7 (2006).
  MedlineGoogle Scholar
• 177 Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10(6), 717–728 (2012).
  Medline CASGoogle Scholar
• 178 Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138(5), 822–829 (2009).
  Medline CASGoogle Scholar
• 179 Dick JE. Stem cell concepts renew cancer research. Blood 112(13), 4793–4807 (2008).
  Medline CASGoogle Scholar
• 180 Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum. Pathol. 44(11), 2373–2384 (2013).
  Medline CASGoogle Scholar
• 181 Li X, Lewis MT, Huang J et al. Intrinsic resistance of Wigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100(9), 672–679 (2008).
  Medline CASGoogle Scholar
• 182 Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg. Oncol. 19(1), 27–32 (2010).
  MedlineGoogle Scholar
• 183 Wang N, Wang Z, Peng C et al. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis 35(11), 2544–2554 (2014).
  Medline CASGoogle Scholar
• 184 Wang Z, Wang N, Li W et al. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway. Carcinogenesis 35(10), 2346–2356 (2014).
  Medline CASGoogle Scholar
• 185 Saha S, Mukherjee S, Mazumdar M et al. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Transl. Res. 165(5), 558–577 (2015).
  Medline CASGoogle Scholar
• 186 Bozorgi A, Khazaei M, Khazaei MR. New findings on breast cancer stem cells: a review. J. Breast Cancer 18(4), 303–312 (2015).
  MedlineGoogle Scholar
• 187 Duru N, Fan M, Candas D et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin. Cancer Res. 18(24), 6634–6647 (2012).
  Medline CASGoogle Scholar
• 188 Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother. Oncol. 108(3), 378–387 (2013).
  MedlineGoogle Scholar
• 189 Guo W. Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl. Med. 3(8), 942–948 (2014).
  Medline CASGoogle Scholar
• 190 Camerlingo R, Ferraro GA, De Francesco F et al. The role of CD44⁺/CD24^-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol. Rep. 31(3), 1127–1132 (2014).
  Medline CASGoogle Scholar
• 191 Ricardo S, Vieira AF, Gerhard R et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64(11), 937–946 (2011).
  MedlineGoogle Scholar
• 192 Kang EJ, Jung H, Woo OH et al. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma 61(3), 352–362 (2014).
  Medline CASGoogle Scholar
• 193 Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O. Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows. Pers. Med. 8(3), 321–330 (2011). •• Presenting innovative technology for breast cancer risk assessment and providing recommendations for clinical application.
  Google Scholar
• 194 Grech G, Zhan X, Yoo BC et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 6(1), 9 (2015).
  MedlineGoogle Scholar
• 195 Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 3(1), 14 (2012).
  MedlineGoogle Scholar